A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

This trial is for veterans with a type of blood cancer called chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are already being treated with a BTK inhibitor drug (like ibrutinib, acalabrutinib, or zanubrutinib). It is testing whether adding venetoclax (a second targeted cancer drug) can improve outcomes. **You may be eligible if...** - You have been diagnosed with CLL or SLL - You have been on a BTK inhibitor for at least 6 months with a stable dose for the last 3 months - You are 18 or older and in reasonably good health (ECOG 0–2) - Your disease is still detectable (in blood tests or imaging) - Your lymph nodes are less than 5 cm and your white cell count is not extremely high (low tumor lysis risk) **You may NOT be eligible if...** - Your CLL or SLL has progressed while on the BTK inhibitor - You have previously received a BTK inhibitor combined with venetoclax - You have a history of Richter's transformation (conversion to a more aggressive lymphoma) - You have active hepatitis B - You have problems absorbing oral medications Talk to your doctor to see if this trial is right for you.